BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240229T090000
DTEND;TZID=Europe/Brussels:20240301T170000
DTSTAMP:20240214T100345Z
CREATED:20240214T085311Z
LAST-MODIFIED:20240214T100345Z
UID:7415-1709197200-1709312400@www.europabio.org
SUMMARY:International Congress on Rare Diseases and Orphan Drugs 2024
DESCRIPTION:Navigating the Uncharted: Advancements\, Collaborations\, and Hope in Rare Diseases \n\n\n\nSupported by EuropaBio \n\n\n\n \n\n\n\nAbout the event: \n\n\n\nEmbrace the extraordinary journey into the world of rare diseases at our groundbreaking International Congress\, where innovation\, collaboration\, and hope converge! \n\n\n\nThe International Congress on Rare Diseases and Orphan Drugs is organized by Rare Diseases Greece (RDG)\, member of EURORDIS-Rare Diseases Europe and Boussias Events. \n\n\n\nFollowing the success of the previous years and having advanced the policy agenda on both a national and international level\, the Organizing Committee – consisting of Rare Diseases Greece (RDG)\, the 30-member umbrella organization that represents the country’s rare disease community\, brings together all the key initiatives and stakeholders currently shaping the rare disease landscape with the aim to set a course for the future of rare diseases. \n\n\n\nAttendance details: \n\n\n\nThursday\, 29.02.2024 (Hybrid | Technopolis City of Athens Gasholder 1 – Auditorium “Miltiadis Evert”) & Friday\, 01.03.2024 (Digital) \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nFind out more here
URL:https://www.europabio.org/event/international-congress-on-rare-diseases-and-orphan-drugs-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banner-International-Congress-on-Rare-Diseases-Orphan-Drugs-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240307T130000
DTEND;TZID=Europe/Brussels:20240307T143000
DTSTAMP:20240306T151454Z
CREATED:20240209T095401Z
LAST-MODIFIED:20240306T151454Z
UID:7385-1709816400-1709821800@www.europabio.org
SUMMARY:EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
DESCRIPTION:Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies. \n\n\n\nFollowing the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem\, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe\, EU patients and economies within a global race towards health security and competitiveness. \n\n\n\nThe event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients. \n\n\n\nThe webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend\, please register below. \n\n\n\nAgenda: \n\n\n\n\nWelcome & Introduction: 13:00 – 13:05\, Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n\nReport Presentation and Q&A: 13:05 – 13:30\, Antun Sablek & Tim Wilsdon\, Charles River Associates\n\n\n\nPanel Discussion and Q&A: 13:30 – 14:25\, Panelists: John James Ricketts\, Noel Minnis\, Thomas Bols\, Tineke Van hooland\, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.\n\n\n\nConcluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n \n\n\n\nSpeakers: Moderated by Dr Claire Skentelbery\, EuropaBio \n\n\n\n\nAntun Sablek\, Charles River Associates\n\n\n\nJohn James Ricketts\, Eli Lilly\n\n\n\nNoel Minnis\, Takeda\n\n\n\nThomas Bols\, PTC Therapeutics\n\n\n\nTim Wilsdon\, Charles River Associates\n\n\n\nTineke Van hooland\, Bio.be\n\n\n\nWojciech Nowak\, Novartis\n\n\n\nYordan Aleksandrov\, Pfizer\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/europabio-webinar-how-will-the-revision-eu-general-pharmaceutical-legislation-impact-europes-innovation-ecosystem-and-biotechnology-companies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/CRA-Webinar-Banner-Event-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240313T130000
DTEND;TZID=Europe/Brussels:20240313T200000
DTSTAMP:20240209T113124Z
CREATED:20231213T100000Z
LAST-MODIFIED:20240209T113124Z
UID:7082-1710334800-1710360000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit 2024 - Policy pathways for biomanufacturing in Europe
DESCRIPTION:The Biomanufacturing Policy Summit will host its 2nd edition in March 2024. The invite-only half-day summit hosted by EuropaBio brings together stakeholders including industry representatives and policymakers\, to discuss Europe’s ambitions for biomanufacturing and the tangible legislative\, regulatory and strategic pathways. \n\n\n\n2023 was a year of visibility and recognition for biomanufacturing in Europe. It saw the creation of the Strategic Technologies for Europe Platform (STEP) and the announcement of the EU Biotech and Biomanufacturing Initiative\, plus the identification of biotechnology as a critical technology for Europe’s security. 2024 is expected to be a year in which initiatives gain policy momentum\, within a new Parliament and Commission and begin to deliver practical and impactful instruments to European industries. \n\n\n\n \n\n\n\n13:00 – Lunch14:00 – Welcome & Introduction14:10 – Keynote Speakers15:30 – Defragmenting and Accelerating Europe’s Biotech & Biomanufacturing – The Role of Policy “How does policy impact decisions for biomanufacturing companies in Europe across sectors?”16:15 – Coffee Break16:30 – Out of the Box – A Global View on Biomanufacturing Policies “What can Europe learn and lead from policy across global regions?”17:15 – How does Policy deliver for Biomanufacturing – Looking Ahead “The policy future for Europe\, with recommendations for the incoming Commission and Parliament.”18:00 – Networking Reception \n\n\n\n \n\n\n\nParticipants will discuss how policy enables Europe to seize the opportunity for biomanufacturing within innovative\, sustainable and critical products within global supply chains. The Summit will address policy pathways for how biotech and biomanufacturing can deliver results in competitiveness\, Green Transition and resilience across sectors. \n\n\n\nFor all enquiries\, please contact our Biomanufacturing Platform Coordinator\, Francisco Castro Alves: f.alves@europabio.org
URL:https://www.europabio.org/event/biomanufacturing-policy-summit-2024-policy-pathways-for-biomanufacturing-in-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Event-Banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240319T143000
DTEND;TZID=Europe/Brussels:20240319T164500
DTSTAMP:20240213T093923Z
CREATED:20240213T092326Z
LAST-MODIFIED:20240213T093923Z
UID:7402-1710858600-1710866700@www.europabio.org
SUMMARY:Industrial biotech: Is Europe ready to harness its potential?
DESCRIPTION:A Science | Business closed-door roundtable\, organised in partnership with EuropaBio – followed by networking reception \n\n\n\nOnly By Invitation \n\n\n\n \n\n\nBackground Information \nIn recent years industrial biotechnology – also known as “white” biotech – has emerged as a high-value driver of industrial modernisation and the green transition. Through the innovative use of microorganisms and enzymes\, it has transformative potential for manufacturing\, waste use and the creation of sustainable products in sectors as varied as energy\, textiles\, plastics\, paper\, agriculture and water. While some core processes\, such as fermentation technology\, have been commercially deployed for around 50 years\, the speed of scientific progress and solution development are accelerating exponentially. As such\, it appears that the sector as a whole is truly poised to make the leap from “proof of concept” to mainstream application at the European level.  \nThese take on greater importance when one considers other strategic priorities for the EU. First\, it is clear that for Europe to achieve e.g. its 2030 benchmark for net-zero technology manufacturing in the Green Deal Industrial Plan (GDIP)\, it will need to leverage its full innovation capacity across sectors. Second\, as global demand grows for sustainable solutions to climate\, energy\, biodiversity and food system crises\, Europe is ideally positioned to take market leadership in various domains\, given its research excellence and strong industrial base. And third\, the EU’s proposed Strategic Technologies for Europe Platform (STEP) has already identified biotechnologies among its key value chains to ensure future resilience\, autonomy and competitiveness\, while biotechnology has also been recognised as a critical technology for Europe. \nYet a degree of skepticism remains – both in public and policy circles – about the risk/reward ratio of biotechnologies and their wider value to society. One useful counterpoint is to consider the evolution of health-related biotechnology (often called “red” biotech). Having overcome similar resistance and concerns\, “red” biotech is now deployed at scale throughout the life science and pharmaceutical sectors\, and is acknowledged today as a key component in European health innovation. So how can the lessons learned on that journey be absorbed and applied to other sectors?   \n As the EU prepares for its transition to a new Parliament and Commission\, it is therefore an ideal moment to open a multistakeholder dialogue on how policy and regulatory innovations could increase the European added value of “white” biotech and biomanufacturing in the years to come. This also builds on Ursula von der Leyen’s announcement of a new biotech and biomanufacturing initiative in last September’s state-of-the-union address. Among some of the key issues for consideration: \nWhere can industrial biotech and biomanufacturing contribute most effectively to the GDIP and STEP\, and what are the longer-term implications for boosting the global competitiveness of European companies?\nWhat should underpin a future EU roadmap for advancing “white” biotech and biomanufacturing across sectors\, in line with other long-term strategies and objectives?\nWhich other steps are needed at EU and national level to build future capacity\, such as infrastructure and skills?\nIn which ways can public and private finance best support pioneering “white” biotech firms – large and small – in scaling up and maturing their solutions to market-readiness and mass production levels\, as has happened in the health sector?\nBeyond the CBE Joint Undertaking\, to what extent could Horizon Europe\, FP10 and other key instruments – such as the new biotech & biomanufacturing initiative – strengthen Europe’s industrial biotech R&D ecosystem in the next policy cycle?\nOn March 19\, Science|Business\, in cooperation with EuropaBio\, will convene a select group of senior figures and experts from across the industrial biotech spectrum to address these issues in a closed-door\, invitation-only roundtable. Drawing in part on latest research and real-world applications\, the meeting will identify recommendations to harness the full potential of “white” biotech and biomanufacturing\, and to align its further development with the realisation of key EU policy goals.\n \n \n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFor more information\, please contact: denitsa.nikolova@sciencebusiness.ne \n\n\n\n \n\n\n\n \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/industrial-biotech-is-europe-ready-to-harness-its-potential/
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banners-Website-1.png
END:VEVENT
END:VCALENDAR